NEW YORK, July 21, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a Notice of Allowance from the Japanese Patent Office related to the Company’s RECALL-VAXTM technology platform. Patents for RECALL-VAXTM have been previously issued in Europe, the United States and other countries. RECALL-VAXTM is a method to immunize presymptomatic or symptomatic patients to produce highly specific natural antibodies against the beta amyloid (“Aß”) protein without interfering with the functions or metabolism of the important Amyloid Precursor Protein present at the connections between nerve cells.
